Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti...
https://pubmed.ncbi.nlm.nih.gov/35749004/Actively Recruiting
Led by Hospital Universitario Dr. Jose E. Gonzalez · Updated on 2025-03-20
10
Participants Needed
1
Research Sites
12 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of a low-dose, limited-duration teclistamab treatment as a consolidation therapy for patients newly diagnosed with multiple myeloma NDMM. This single-arm, open-label phase 2 study aims to understand how well this treatment works following initial therapy with three cycles of a combination regimen called VRd, which includes bortezomib, lenalidomide, and dexamethasone. Participants will first receive three cycles of the VRd induction therapy. Afterward, they will receive four doses of teclistamab at 1.0 mgkg given under the skin. Four weeks after the last teclistamab dose, their clinical response will be evaluated using standard criteria. Those achieving complete response CR or better will undergo further testing for minimal residual disease MRD. Depending on MRD results and risk status, participants will either be monitored for 18 months or receive biweekly bortezomib maintenance. Those with less than CR may receive additional teclistamab doses or exit the study to continue standard care. Throughout the study, participants will be monitored for their response to treatment, including assessments of disease status and side effects. The primary outcome is the general response 18 months after the last teclistamab dose. Secondary outcomes include response duration and adverse events over the same period. The study involves follow-up care based on individual responses and continued monitoring for up to 18 months after treatment.
CONDITIONS
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
D
David Gomez-Almaguer, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Universitario Dr. Jose E. Gonzalez
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of 3 VRd cycles plus consolidation with 4 doses of teclistamab
Participants receive 3 cycles of induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd), followed by 4 therapeutic doses of low-dose teclistamab given subcutaneously as consolidation treatment.
Multiple visits for 3 VRd cycles and 4 teclistamab doses
Duration - Up to 18 months after last teclistamab dose
Four weeks after the last teclistamab dose, participants have their clinical response assessed. Those with complete response and negative measurable residual disease (MRD) enter active surveillance for 18 months. Those with positive MRD or high risk receive biweekly bortezomib maintenance. Participants with very good partial response or worse may receive 1-2 additional teclistamab doses and be reassessed. Participants not achieving complete response exit the study and continue standard care.
Regular assessments during 18-month surveillance or maintenance period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti...
https://pubmed.ncbi.nlm.nih.gov/35749004/Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk...
https://pubmed.ncbi.nlm.nih.gov/34388396/Hospital Universitario Dr. Jose E. Gonzalez
Lead Sponsor